Admissions:
None
Delistings:
G3 Exploration (G3E.L) has left the Main Market
Potential** Initial Public Offerings:
9th May: iFOREX Financial Trading, the fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference, announces that it has confirmed its intention to IPO onto the Main Market. The Company developed and operates a proprietary online and mobile CFD trading platform, allowing primarily retail clients to trade CFDs across 870+ financial instruments, including currencies, commodities, indices, stocks, cryptocurrencies and exchange traded funds. For the year ended 31 December 2024, trading income was $50.1m, adjusted EBITDA of $9.7m and adjusted profit before tax of $7.6m. The current intention is to maintain a progressive dividend policy, and the dividend for FY2025 is expected to be set at approximately 50 per cent. of adjusted profits. Deal size TBC but timing is expected late June 2025.
Market Movers:
Updated 4 June 2025: Ajax Resources (AJAX.L) is planning to move to the Aquis Stock Exchange Growth Market Access Category from the Main Market of the London Stock Exchange. The Company expects cancellation to take place at 08:00 BST on 18 June 2025, with Admission to trading on AQSE to occur concurrently. Ajax is pursuing a strategy as a natural resources investment company, with a focus on Copper, Gold, Zinc, Uranium, and Lead. The Company completed its first acquisition on 21 May 2025. The Company’s first acquisition was the purchase of Puna Metals S.A., holding the mining rights for 12 licences, collectively forming the Eureka Gold and Copper project in the north-west corner of the Province of Jujuy in Argentina.
Reverse Transactions:
20 March 2025: File Forge Technology (AQSE: FILE) the investment Company has approved the acquisition of 100% of the issued share capital of Amirose London Limited from Epoque Services Incorporated Limited for a consideration of £5m, to be satisfied in shares. Given the size of the acquisition relative to File Forge technology PLC and voting control, the acquisition qualifies as a reverse takeover. Amirose London Limited provides contract manufacturing services in the personal care sector for global and boutique premium brands. Amirose London Limited will assist Brands in developing formulations for personal care products, sourcing packaging, bulk manufacturing, filling, and distributing. On Admission, File Forge Technology PLC is to change its name to Amirose London Holdings PLC. Expected Admission date is 6th June 2025
All Things Considered Group 90p £14.89m (AQSE:ATC)
The independent music company offering talent management, live booking, merchandising, talent services and events, report finals to December 2024. Revenue increased by 111% to £50.9m driven by continued organic growth particularly in Artist Representation Services and a £3.1m contribution from Live Events and Experiences. The adjusted operating EBITDA of £1.6m compares to £0.4m loss reducing the FY loss to £0.27m from £3.06m. There is continued investment in the international footprint with a new office in Los Angeles expanding the Group to circa 200 employees across five offices.
Ariana Resources 1.075p £20.9M (AAU.L)
The mineral exploration and development company with gold project interests in Africa and Europe, announces the cold-commissioning of the processing plant at the Tavsan Mine in Turkey. The Project is 23.5% owned by Ariana and the cold-commissioning will be completed in stages through June 2025, following recent connection to grid power. The first ore loading is expected from late June and the processing plant is expected to be fully operational from July, with gold production from the heap-leach underway. This is the Group’s first heap-leach operation in Turkey and there is about a year's worth of ore production at grades ranging from 1.2 to 0.7 g/t Au with the first gold pouring expect this summer.
Bluebird Mining Ventures 0.275p £2.1m (BMV.L)
The Asian gold project development company, updates on the monetisation strategy of the Company's flagship Philippine project. After the renewal of the permit discussions have progressed with the Philippine partner to an advanced stage whereby the Company now expects to conclude an agreement shortly that would effectively extend the Company's free carry all the way through to production. The Company is seeking to retain a net profit interest in the Philippine project throughout the life of mine, importantly without any of the associated costs. A new innovative approach is being adopted as there is an opportunity to convert future revenues from its mining projects into bitcoin mining. The CEO considers that by adopting a 'gold plus a digital gold' strategy, it offers the Company an opportunity look to the future.
Great Southern Copper 3.4p £19.07m (GSCU.L)
The company focused on copper-gold exploration in Chile, reports the exploration geophysics surveys has commenced at the Cerro Negro prospect. The survey results will be to assist in targeting Phase III exploration drilling at Cerro Negro up to two kilometres south of the Mostaza mine where Phase I drilling intersected significant Cu-Ag mineralisation and Phase II drilling results are pending. Phases I and II relied on surface exploration results which will now be explored deeper, both beneath the known mineralisation at Mostaza and along trend to the south. These important geophysical surveys will play a critical role in guiding Phase III exploration drilling.
Helix Exploration 17.5p £27.47m (HEX.L)
The helium exploration and development company with near-term production assets within the 'Montana Helium Fairway’ updates on drilling and announces a fundraise for £4.5m at 16p a share. The funds are to be used for drilling a 4th and 5th production well at Rudyard and invest in plant construction. As the Company pursues its strategic objectives of entering first helium production by the end of summer 2025 and accelerating project ramp up to full scale production. Drilling was successfully completed
at the Weil 1 well at the Rudyard Field in northern Montana. Helix now has three confirmed production wells and which firmly establishes the Rudyard field as a robust, near-term helium producing field.
Jubilee Metals 3.9p £119.8m (JLP.L)
The diversified metals producer with operations in South Africa and Zambia, has received a conditional binding offer for the Group's chrome and PGM operations in South Africa for a consideration of up to $90m. The Binding Offer is subject to several customary conditions including entering into final agreements and obtaining shareholder approval. The South African business has reached a stage of maturity that would require a large capital outlay to achieve any step change in production. The Board considers it is an opportune time to accept a fair value offer for these operations as it allows the Group to wholly focus its efforts on Zambia where there are material opportunities to expand the portfolio of copper producing assets.
Mila Resources 0.925p £5.01m (MILA.L)
The gold exploration company reports results from two additional holes from the Phase 1 drilling programme at the Yarrol Gold Project in Queensland, Australia. The programme is designed to test extensions at depth and along strike of the historic resource envelope in the southern area of the licence and step out into previously untested parallel zones in the northern area. These results bring the total reported to four holes out of ten drilled in the current campaign and confirmed multiple mineralised zones and importantly have intercepted mineralisation outside the historical drilled area reinforcing the potential for resource growth at depth. There are six more holes still to come, and the management are confident in Yarrol's potential to deliver a much larger gold system.
Ondine Biomedical 9p £37.67m (OBI.L)
The life sciences company with light-activated antimicrobial therapies for the prevention and treatment of infections, reports a new client. Canada’s largest cardiac care centre has adopted the Group’s patient Steriwave, recognising the proven track record of improving surgical outcomes and reducing healthcare costs. The photodisinfection will be used as standard of care for all cardiac surgeries. The continuation of Steriwave’s clinical deployments are a result of proving significant reductions in SSI (surgical site infection) rates, so validating it as an effective and innovative solution for infection control.
RM 101p £84.1m (RM.L)
The global EdTech, digital learning and assessment solutions provider, has launched its adaptive virtual accreditation RM Ava platform. This follows £12m of investment since 2024 and brings together the Company's existing tools for assessment onto one single-sign-on cloud-based platform. It is designed to enable the transition from paper to digital learning and examinations and provide solutions to its customers' assessment needs. It is a major step forward in the growth strategy as the expanded feature-set of the platform will also allow RM to extend its product offering and open new customer opportunities within further education and professional qualifications. In 2024, RM won the two largest contracts in its 50-year history with the International Baccalaureate and Cambridge University Press
Tern 1.85p £10.95m (TERN.L)
The investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology reports finals to FY December 2024. The FY net assets are £10.7m, a reduction of £1.6m from December 2023. The fee income reduced to £17k from £199k and the total comprehensive loss for the year was £3.8m compared to a £12.6m loss. Primarily due to a negative £2.5m movement in the fair value of one of its investments. During the year, £1.1m was used in the Company's operations, and £0.8m was deployed within the existing portfolio, via equity and loan investments. The new chairman states that Tern is set to benefit from growing interest in early-stage software and the generative AI space.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
